Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025

Cullinan and Taiho previously announced the Phase 2b portion of the study met the primary endpoint of overall response rate

Cullinan and Taiho previously announced the Phase 2b portion of the study met the primary endpoint of overall response rate